7116-35-0

Usage

InChI:InChI=1/C11H13ClO2/c1-2-14-11(13)7-6-9-4-3-5-10(12)8-9/h3-5,8H,2,6-7H2,1H3

Upstream product

• 2373-88-8 ethyl (E)-3-(3-chlorophenyl)prop-2-enoate 
• 2373-88-8 3-(3-chloro-phenyl)-acrylic acid ethyl ester 
• 141-78-6 ethyl acetate 
• 620-20-2 1-Chloro-3-chloromethyl-benzene 
• 587-04-2 m-Chlorobenzaldehyde 
• 1866-38-2 3-chlorocinnamic acid 

Downstream Products

• 22991-03-3 3-(3-chlorophenyl)propanol 
• 63204-32-0 5-(3-chlorobenzyl)-1,2-dihydro-2-thioxo-4(3H)-pyrimidinone 
• 21640-48-2 3-chlorohydrocinnamic acid 
• 40478-50-0 3-(3-chlorophenyl)propionyl chloride 
• 42348-86-7 5-chloro-1-indanone 
• 1370228-04-8 1,4-diethyl 2-[(3-chlorophenyl)methyl]-3-oxobutanedioate 
• 90347-05-0 1-Chlor-3-<3-chlor-phenyl>-propan 
• 22991-04-4 1-Cyan-3-(3-chlor-phenyl)-propan 
• 63204-33-1 5-(3-chlorobenzyl)-2-methylthio-4-pyrimidone 
• 63204-15-9 2-[2-(5-Methyl-4-imidazolylmethylthio)ethylamino]-5-(3-chlorobenzyl)-4-pyrimidone dihydrochloride 
• 1027018-75-2 C₂₉H₂₅ClN₂O₇ 
• 156176-25-9 Acetic acid 2-[5-(3-chloro-benzyl)-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethoxy]-ethyl ester 
• 156176-38-4 5-(3-Chloro-benzyl)-1H-pyrimidine-2,4-dione 

Relevant academic research and scientific papers

Diboron-Mediated Rhodium-Catalysed Transfer Hydrogenation of Alkenes and Carbonyls

A diboron-mediated rhodium-catalysed transfer hydrogenation system using water as the hydrogen donor is developed. In addition to a series of alkenes with good functional group tolerance, this rhodium-based catalytic system also effectively reduces aldehydes and ketones. A plausible mechanism involving the RhI-catalysed hydrogen generation and Rh0-catalysed hydrogenation is proposed for the reaction.

Preparation method for indanone compound

The invention especially relates to a preparation method for an indanone compound, belonging to the field of organic synthesis. The preparation method for the indanone compounds comprises the following steps: 1) subjecting a compound as shown in a formula I and a compound as shown in a formula II to a condensation reaction so as to prepare a compound as shown in a formula III; 2) subjecting the compound as shown in the formula III to hydrolysis in the presence of alkali so as to prepare a compound as shown in a formula IV; and 3) carrying out acylation and ring closure on the compound as shownin the formula IV so as to prepare the as shown in a formula V. Compared with the prior art, the preparation method for the indanone compound in the invention has the advantages of low raw material cost, simple operation, low production of waste water, waste gas and industrial residues, high yield and the like, and is more suitable for industrial production; and compared with various traditionalpreparation methods for the indanone compound, the preparation method of the invention has obvious advantages and shows good industrialization prospects.

7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS

The compounds of formula (I) are antagonists of the CCR2 receptor Wherein R1-7 and A are as defined in the claims.

7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS

The compounds of formula (I) are antagonists of the CCR2 receptor Wherein R1-7 and A are as defined in the claims.

Inhibition of uridine phosphorylase: Synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2- hydroxyethoxy)methyl]-5-benzyluracils

A series of 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils were synthesized and tested for inhibition of murine liver uridine phosphorylase (UrdPase). Inhibitors of UrdPase are reported to enhance the chemotherapeutic utility of 5-fluoro-2'-deoxyuridine and 5-fluorouracil and to ameliorate zidovudine- induced anemia in animal models. We prepared a series of 5-aryl-substituted analogues of 5-benzylacyclouridine (BAU), a good inhibitor of UrdPase (IC50 of 0.46 μM), to develop a compound with enhanced potency and improved pharmacokinetics. The first phase of structure-activity relationship studies on a series of 32 aryl-substituted 5-benzyluracils found several 5-(3- alkoxybenzyl) analogues of 5-benzyluracil with enhanced potency. The acyclovir side chain, the (2-hydroxyethoxy)methyl group, was substituted on the more potent aryl-substituted 5-benzyluracils. The two most potent compounds, 10y (3-propoxy) and 10dd (3-sec-butoxy), were inhibitors of UrdPase with IC50s of 0.047 and 0.027 μM, respectively. Six compounds were tested in vivo for effects on steady-state concentrations of circulating uridine in rats. Plasma uridine levels were elevated 3-9-fold by compound levels that ranged from 8 to 50 μM.